The role of multidrug resistance-associated protein (MRP) expression in multidrug resistance

Anti-Cancer Drugs

Volumn 8, Issue 1, 1997, Pages 17-25

  Kavallaris, Maria ^a  

^a SYDNEY CHILDREN'S HOSPITAL   (Australia)

Author keywords

multidrug resistance; multidrug resistance associated protein

Indexed keywords

2 [1 (3 DIMETHYLAMINOPROPYL) 3 INDOLYL] 3 (3 INDOLYL)MALEIMIDE; AMIODARONE; ANTINEOPLASTIC AGENT; BUTHIONINE SULFOXIMINE; CISPLATIN; CYCLOSPORIN A; DAUNORUBICIN; DIFLOXACIN; DOXORUBICIN; ETOPOSIDE; GENISTEIN; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN; NICARDIPINE; RHODAMINE; VALSPODAR; VERAPAMIL; VERLUKAST; VINBLASTINE;

CANCER CHEMOTHERAPY; GENE EXPRESSION; HUMAN; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; REVIEW;

ANIMALS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; GENES, MDR; HUMANS;

EID: 0031043119     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199701000-00002     Document Type: Review

References (93)

1. Gottesman MM, Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 1993; 62: 385-427.
2. Roepe PD. The role of the MDR protein in altered drug translocation across tumor cell membranes. Biochim Biophy Acta 1995; 1241: 385-406.
3. Roninson IB, Pastan I, Gottesman MM. Isolation and characterisation of the human MDR (P-glycoprotein) genes. In: Roninson IB, ed. Molecular and cellular biology of multidrug resistance in tumor cells. New York: Plenum 1991: 91-106.
4. Beck WT, Danks MK: Characteristics of multidrug resistance in human tumor cells. In: Roninson IB, ed. Molecular and cellular biology' of multidrug resistance in tumor cells. New York: Plenum 1991: 3-46.
5. Fojo AT, Ueda K, Slamon DJ, Poplack DG, Gottesman MM, Pastan I. Expression of a multidrug-resistance gene in human tumors and tissues. Proc Natl Acad Sci USA 1987; 84: 265-9.
6. Goldstein LJ, Galski H, Fojo A, et al. Expression of a multidrug resistance gene in human cancers. J Natl Cancer Inst 1989; 81: 116-24.
7. Marsh W, Sicheri D, Center MS. Defective in the initial intracellular accumulation of drug. Cancer Res 1986; 46: 4053-7.
8. Twentyman PR, Fox NE, Bleehen NM. Drug resistance in human lung cancer cell lines: cross resistance studies and effects of the calcium transport blocker, verapamil. Int J Radiat Oncol 1986; 12: 1355-8.
9. Zijlstra JC, de Vries EGE, Mulder NH. Multifactorial drug resistance in an Adriamycin-resistant human small cell lung carcinoma cell line. Cancer Res 1987; 47: 1780-4.
10. McGrath T, Center MS. Mechanisms of multidrug resistance in HL60 cells: evidence that a surface membrane protein distinct from P-glycoprotein contributes to reduced cellular accumulation of drug. Cancer Res 1988; 48: 3959-63.
11. Mirski SEL, Gerlach JH, Cole SPC. Multidrug resistance in human small cell lung cancer cell line selected in adriamycin. Cancer Res 1987; 47: 2594-8.
12. Slovak ML, Hoeltge GA, Dalton WS, Trent JM. Pharmacological and biological evidence for differing mechanisms of doxorubicin resistance in two human tumour cell lines. Cancer Res 1988; 48: 2793-7.
13. Kuiper CM, Broxterman JJ, Baas F, et al. Drug transport variants without P-glycoprotein overexpression from a human squamous lung cancer cell line after selection with doxorubicin. J Cell Pharmacol 1990; 1: 35-41.
14. Cole SPC, Bhardwaj G, Gerlach JH, et al. Overexpression of a transport gene in a multidrug-resistant human lung cancer cell line. Science 1992; 258: 1650-4.
15. Grant CE, Valdimarsson G, Hipfner DR, Amquist KC, Cole SPC, Deeley RG. Overexpression of multidrug resistance-associated protein (MRP) increases to natural product drugs. Cancer Res 1994; 54: 357-61.
16. Cole SPC, Deeley RG. Multidrug resistance-associated protein: sequence correction. Science 1993; 260: 879.
17. Slovak ML, J.P. H, Bhardwaj G, Kurtz EU, Deeley RG, Cole SPC. Localisation of a novel multidrug resistance-associated gene in the HT1080/DR4 and H69AR human tumor cell lines. Cancer Res 1993; 53: 3221-5.
18. Kuss BJ, Deeley RG, Cole SPC, et al. Deletion of gene for multidrug resistance in acute myeloid leukaemia with inversion in chromosome 16: prognostic implications. Lancet 1994; 343: 1531-4.
19. Cole SPC, Sparkes KE, Fraser K, et al. Pharmacological characterisation of multidrug resistant MRP-transfected human tumor cells. Cancer Res 1994; 54: 5902-10.
20. Muller M, Meijer C, Zaman GJR, et al. Overexpression of the gene encoding the multidrug resistance-associated protein results in increased ATP-dependent glutathione S-conjugate transport. Proc Natl Acad Sci USA 1994; 91: 13033-7.
21. Kruh GD, Chan A, Myers K, Gaughan K, Miki T, Aaronson SA. Expression complimentary DNA library transfer establishes mrp as a multidrug resistance gene. Cancer Res 1994; 54: 1649-52.
22. Zaman GJR, Flens MJ, van Leusden MR, et al. The human multidrug-resistance-associated protein MRP is a plasma membrane drug-efflux pump. Proc Natl Acad Sci USA 1994; 91: 8822-6.
23. Aguilar-Bryan L, Nichols CG, Wechsler SW, et al. Cloning of the β cell high affinity sulfonylurea receptor: a regulator of insulin secretion. Science 1995; 268: 423-6.
24. Szczypka MS, Wemmie JA, Moye-Rowley WS, Thiele DJ. A yeast metal resistance protein similar to human cystic fibrosis transmembrane conductance regulator (CFTR) and multidrug resistance-associated protein. J Biol Chem 1994; 269: 22853-7.
25. Stride BD, Valdimarsson G, Gerlach JH, Wilson GM, Cole SPC, Deeley RG. Structure and expression of the messenger RNA encoding the murine multidrug resistance protein, an ATP-binding cassette transporter. Mol Pharmacol 1996; 49: 962-71.
26. Loe DW, Deeley RG, Cole SPC. Biology of the multidrug resistance-associated protein, MRP Eur J Cancer 1996; 32A: 945-57.
27. Bakos E, Hegedus T, Hollo Z, et al. Membrane topology and glycosylation of the human multidrug resistance-associated protein. J Biol Chem 1996; 271: 12322-6.
28. Almquist KC, Loe DW, Hipfner DR, Mackie JE, Cole SPC, Deeley RG. Characterisation of the Mr 190,000 multidrug resistance protein (MRP) in drug-selected and transfected human tumor cells. Cancer Res 1995; 55: 102-10.
29. Ma L, Krishnamachary N, Center MS. Phosporylation of the multidrug resistance associated protein gene encoded protein P190. Biochemistry 1995; 34: 3338-42.
30. Germann UA. P-glycoprotein - a mediator of multidrug resistance in tumour cells. Eur J Cancer 1996; 32A: 927-44.
31. Zaman GLR, Verstantvoort CHM, Smit JJM, et al. Analysis of the expression of MRP, the gene for a new putative transmembrane drug transporter, in human multidrug-resistant lung cancer cell lines. Cancer Res 1993; 53: 1747-50.
32. Eijdems EWHM, de Haas M, Coco-Martin JM, et al. Mechanisms of MRP over-expression in four human lung-cancer cell lines and analysis of the MRP amplicon. Int J Cancer 1995; 60: 676-84.
33. Slapak CA, Fracasso PM, Martell RL, Toppmeyer DL, Lecerf J-M, Levy SB. Overexpression of the multidrug resistance-associated protein (MRP) in vincristine but not doxorubicin-selected multidrug-resistant murine erythroleukemia cells. Cancer Res 1994; 54: 5607-13.
34. Giaccone G, van Ark-Otte J, Rubio GJ, et al. MRP is frequently expressed in human lung-cancer cell lines, in non-small-cell lung cancer and in normal lung, Int J Cancer 1996; 66: 760-7.
35. Krishnamachary N, Center MS. The MRP gene associated with a non-P-glycoprotein multidrug resistance encodes a 190-kDa membrane bound glycoprotein. Cancer Res 1993; 53: 3658-61.
36. Flens MJ, Izquierdo MA, Scheffer GL, et al. Immunochemical detection of the multidrug resistance-protein MRP in human multidrug-resistant tumor cells by monoclonal antibodies. Cancer Res 1994; 54: 4557-63.
37. Hipfner DR, Gauldie SD, Deeley RG, Cole SPC. Detection of the Mr 190,000 multidrug resistance protein. MRP with monoclonal antibodies. Cancer Res 1994; 54: 5788-92.
38. Breuninger LM, Paul S, Gaughan K, et al. Expression of multidrug resistance-associated protein in NIH/3T3 cells confers multidrug resistance associated with increased efflux and altered intracellular drug distribution. Cancer Res 1995; 55: 5342-7.
39. Cole SPC, Chanda ER, Dicke FP, Gerlach JH, Mirski SEL. Non-P-glycoprotein-mectiated multidrug resistance in a small cell lung cancer cell line: evidence for decreased susceptibility to drug-induced DNA damage and reduced levels of topoisomerase II. Cancer Res 1991; 51: 3345-52.
40. Jedlitschky G, Leier I, Buchholz U, Center M, Keppler D. ATP-dependent transport of glutathione S-conjugates by the multidrug resistance-associated protein. Cancer Res 1994; 54: 4833-6.
41. Leier I, Jedlitschky G, Buchholz U, Cole SPC, Deeley RG, Keppler D. The MRP gene encodes an ATP-dependent export pump for leukotriene C-4, and structurally related conjugates. J Biol Chem 1994; 269: 27807-10.
42. 4 and chemotherapeutic agents in membrane vesicles. J Biol Chem 1996; 271: 9675-82.
43. Keppler D. Leukotrienes: biosynthesis, transport, inactivation, and analysis Rev Physiol Biochem Pharmacol 1992; 121: 1-30.
44. Oude Elferink RPJ, Jansen PLM. The role of the canalicular multispecific organic anion transporter in the disposal of endo- and xenobiotics. Pharmacol Ther 1994; 64: 77-97.
45. McGrath T, Latoud C, Arnold ST, Safa AR, Felsted RL, Center MS. Mechanisms of multidrug resistance associated membrane proteins and levels of mdr gene expression. Biochem Pharmacol 1989; 38: 3611-9.
46. Versantvoort CHM, Broxterman HJ, Bagrij T, Scheper RJ, Twentyman PR. Regulation of glutathione of drug transport in multidrug resistant human lung tumour cell lines overexpressing MRP. Br J Cancer 1995; 72: 82-9.
47. Zaman GJR, Lankelma J, van Tellingen O, et al. Role of glutathione in the export of compounds from cells by the multidrug-resistance-associated protein. Proc Natl Acad Sci USA 1995; 92: 7690-4.
48. Ishikawa T, Akimaru K, Kuo MT, Priebe W, Suzuki M. How does the MRP/GS-X pump export doxorubicin? [Letter]. J Natl Cancer Inst 1995; 87: 1639-40.
49. Jedlitschky G, Leier I, Buchholz D, Barnouin K, Kurz G, Keppler D. Transport of glutathione, glucoronate, and sulfate conjugates by the MRP gene-encoded conjugate export pump. Cancer Res 1996; 56: 988-94.
50. Paul S, Breuninger LM, Tew KD, Shen H, Kruh GD. ATP-dependent uptake of natural product cytotoxic drugs by membrane vesicles establishes MRP as a broad specificity transporter. Proc Natl Acad Sci USA 1996; 93: 6929-34.
51. Ishikawa T, Bao J-J, Yamane Y, et al. Coordinated induction of MRP/GS-X pump and γ-glutamylcysteine synthetase by heavy metals in human leukemia cells. J Biol Chem 1996; 271: 14981-8.
52. Antitumor drug resistance. In Fox BW, Fox M, eds. Handbook of experimental pharmacology. Berlin: Springer-Verlas 1984.
53. Broxterman HJ, Lankelma J, Pinedo HM. How to probe clinical tumour samples for P-glycoprotein and multidrug resistance-associated protein. Eur J Cancer 1996; 32A: 1024-33.
54. Cole SPC, Downes HF, Slovak ML. Effect of calcium antagonists on the chemosensitivity of two multidrug-resistant human tumour cell lines which do not overexpress P-glycoprotein. Br J Cancer 1989; 59: 42-6.
55. Binaschi M, Supino R, Gambetta RA, et al. MRP gene overexpression in a human doxorubicin-resistant SCLC cell line: alterations in cellular pharmacokinetics and in pattern of cross resistance. Int J Cancer 1995; 62: 84-9.
56. Abe T, Koike K, Ohga T, et al. Chemosensitization of spontaneous multidrug resistance by a 1,4-dihydropyridine analogue and verapamil in human glioma cell lines. Br J Cancer 1995; 72: 418-23.
57. Davey RA, Longhurst TJ, Davey MW, et al. Drug resistance mechanisms and MRP expression in response to epirubicin treatment in a human leukaemia cell line. Leuk Res 1995; 17: 1-8.
58. Tasaki Y, Nakagawa M, Ogata J, et al. Reversal by a dihydropyridine derivative of non-P-glycoprotein-mediated multidrug resistance in etoposide-resistant human prostatic cancer cell line. J Urol 1995; 154: 1210-16.
59. Feller N, Kuiper CM, Lankelma J, et al. Functional detection of MDR1/P170 and MRP/P190-mediated multidrug resistance in tumour cells by flow cytometry. Br J Cancer 1996; 72: 543-9.
60. Barrand MA, Rhodes T, Center MS, Twentyman PR. Chemosensitization and drug accumulation effects of cyclosporin A, PSC-833, and verapamil in human MDR large cell lung cancer cells expressing a 190k membrane protein distinct from P-glycoprotein. Eur J Cancer 1993; 29A: 408-15.
61. van der Graaf WTA, de Vries EGE, Timmer-Bosscha H, et al. Effects of amiodarone, cyclosporin A, and PSC 833 on the cytotoxicity of mitoxanrone, doxorubicin, and vincristine in non-P-glycoprotein human small cell lung cancer cell lines. Cancer Res 1994; 54: 5368-73.
62. Gerkler V, Boer R, Ise W, Sanders KH, Schachtele C, Beck J. The specific bisindolymaleimide PKC-inhibitor GF109203X efficiently modulates MRP-associated multiple drug resistance. Biochem Biophys Res Commun 1995; 206: 119-26.
63. 4 receptor antagonist MK571 specifically modulates MRP associated multidrug resistance. Biochem Biophys Res Commun 1995; 208: 345-52.
64. Versantvoort CHM, Schuurhuis GJ, Pinedo HM, et al. Genistein modulates the decreased drug accumulation in non-P-glycoprotein mediated multidrug resistant tumour cells. Br J Cancer 1993; 68: 939-46.
65. Gollapudi S, Thadepalli F, Kim CH, Gupta S. Difloxacin reverses multidrug resistance in HL-60/AR cells that overexpress the multidrug resistance-related protein (MRP) gene. Oncol Res 1995; 7: 213-25.
66. Griffith OW, Meister A. Potent and specific inhibition of glutathione synthesis by buthionine sulfoximine (S-n-butyl homocysteine sulfoximine). J Biol Chem 1979; 254: 7558-60.
67. Meister A, Anderson ME. Glutathione. Annu Rev Biochem 1983; 52: 711-60.
68. Orr GA, Han EK-H, Browne P, et al. Identification of the major phosphorylation domain of murine mdr1b P-glycoprotein. J Biol Chem 1993; 268: 25054-62.
69. Germann UA, Chambers T, Ambudkar SV, Pastan I, Gottesman MM. Effects of phosphorylation on multidrug resistance. J Bioenerg Biomembr 1995; 27: 53-61.
70. Germann UA, Chambers TC, Ambudkar SV, et al. Characterization of phosphorylation-defective mutants of human P-glycoprotein expressed in mammalian cells. J Biol Chem 1996; 271: 1708-16.
71. Kiehntopf M, Brach MA, Licht T, et al. Ribozyme-mediated cleavage of the MDR-1 transcript restores sensitivity in previously resistant cancer cells. EMKO J 1994; 13: 4645-52.
72. Bertram J, Paifner K, Killian M, et al. Reversal of multiple drug resistance in vitro by phosphorothioate oligonucleotides and ribozymes. Anti-Cancer Drugs 1995; 6: 124-34.
73. Stewart AJ, Canitrot Y, Baracchini E, Dean NM, Deeley RG, Cole SPC. Reduction of expression of the multidrug resistance protein (MRP) in human tumor cells by antisense phosphorothioate oligonucleotides. Biochem Pharmacol 1996; 51: 461-9.
74. Burger H, Nooter K, Zaman GJR, et al. Expression of the multidrug resistance-associated protein (MRP) in acute and chronic leukemias. Leukemia 1994; 8: 990-7.
75. Kruh GD, Gaughan KT, Godwin A, Chan A. Expression pattern of MRP in human and adult solid tumor cell lines. J Natl Cancer Inst 1995; 87: 1256-8.
76. Nooter K, Westerman AM, Flens MJ, et al. Expression of the multidrug resistance-associated protein (MRP) gene in human cancers. Clin Cancer Res 1995; 1: 1301-10.
77. Flens MJ, Zaman GJR, van der Valk P, et al. Tissue distribution of the multidrug resistance protein. Am J Path 1996; 148: 1237-47.
78. Beck J, Niethammer D, Gekeler V. High mdr1- and mrp-, but low topoisomerase IIα-gene expression in B-cell chronic lymphocytic leukaemias. Cancer Lett 1994; 86: 135-42.
79. Hart SM, Ganeshaguru K, Hoffbrand AV, Prentice HG, Mehta AB. Expression of the multidrug resistance-associated protein (MRP) in acute leukemia. Leukemia 1994; 8: 2163-8.
80. Schneider E, Cowan KH, Bader H, et al. Increased expression of the multidrug resistance-associated protein gene in relapsed acute leukemia. Blood 1995; 85: 186-93.
81. Schuurhuis GJ, Broxterman HJ, Ossenkoppele GJ, et al. Functional multidrug resistance phenotype associated with combined overexpression of Pgp/MDR1 and MRP together with 1-β-D-arabinofuranosylcytosine sensitivity may predict clinical response in acute mycloid leukemia. Clin Cancer Res 1995; 1: 81-93.
82. Ross DD, L.A. D, Schiffer CA, et al. Expression of multidrug resistance-associated protein (MRP) mRNA in blast cells from acute myeloid leukaemia (AML) patients. Leukemia 1996; 10: 48-55.
83. Nooter K, Burger H, Stoter G. Multidrug resistance-associated protein (MRP) in haematological malignancies. Leukemia and Lymphoma 1996; 20: 381-7.
84. Bordow SB, Haber M, Madafiglio J, Cheung B, Marshall GM, Norris MD. Expression of the multidrug resistance-associated protein (MRP) gene correlates with amplification and overexpression of the N-myc oncogene in childhood neuroblastoma. Cancer Res 1994; 54: 5036-40.
85. Sugawara I, Masunaga A, Itoyama S, Sumizawa T, Akiyama S, Yamashita T. Expression of multidrug resistance-associated protein (MRP) in thyroid cancers. Cancer Lett 1995; 95: 135-8.
86. Kavallaris M, Leary JA, Barrett JA, Friedlander ML. MDR1 and multidrug resistance-associated protein (MRP) gene expression in epithelial ovarian tumors. Cancer Lett 1996; 102: 7-16.
87. Oda Y, Schneider-Stock R, Rys J, Gruchala A, Niezabitowski A, Roessner A. Expression of multidrug-resistance-associated protein gene in human soft-tissue sarcomas. J Cancer Res Clin Oncol 1996; 122: 161-5.
88. Endo K, Maehara Y, Y I, et al. Multidrug resistance-associated protein expression in clinical gastric carcinoma. Cancer (suppl) 1996; 77: 1681-7.
89. Chuman Y, Sumizawa T, Takebayashi Y, et al. Expression of the multidrug-resistance-associated protein (MRP) gene in human colorectal, gastric and non-small-cell lung carcinomas. Int J Cancer 1996; 66: 274-9.
90. Brodeur GM, Azar C, Brother M, et al. Neuroblastoma: effect of genetic factors on prognosis and treatment. Cancer 1992; 70: 1685-94.
91. Norris MD, Bordow SB, Marshall GM, Haber PS, Cohn SL, Haber M. Expression of the gene for multidrug-resistance-associated protein and outcome in patients with neuroblastoma. N Engl J Med 1996; 334: 231-8.
92. Twentyman PR, Rhodes T, Rayner SA. A comparison of rhodamine 123 accumulation and efflux in cells with P-glycoprotein-mediated and MRP-associated multidrug resistance phenotypes. Eur J Cancer 1994; 30A: 1360-9.
93. Beck WT, Grogan TM, Willman CL, et al. Methods to detect P-glycoprotein-associated multidrug resistance in patients tumors: consensus recommendations. Cancer Res 1996; 56: 3010-20.